Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?

In our study, overall survival showed a trend toward a better survival in the neoadjuvant group, even if it was not statistically significant, and the non-significance may be explained by the small sample size and could be confirmed by larger prospective trials.

also in 53,322 other papers